MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications, and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content, and market expertise into new technology platforms, customer applications, and services. The announcement, made via Media OutReach Newswire, signals a significant strategic shift for the company as it seeks to build scalable products and new business models across markets.
Following the appointment of Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. Goswami stated, "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products, platforms and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve."
Central to this transformation is the expansion of MIMS' Clinical Decision Support (CDS) offerings. The company recently launched MIMS Pulse, a next-generation CDS platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment, and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, the company is scaling eMIMS Plus, a platform that brings MIMS' trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia under Goswami's guidance in his previous role leading the CDS Business, eMIMS Plus is now available in India and Malaysia with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent. MIMS is also developing its global CDS offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments.
In addition to CDS, MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organizations. The business continues to develop digital events, AI-enabled content capabilities, and new customer engagement models. MIMS is exploring more connected, intelligence-led services to help healthcare and life sciences organizations better understand their markets, engage healthcare professionals, and make more informed decisions. This work represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services.
The implications of these developments are significant for the healthcare industry and for MIMS' stakeholders. By leveraging its six decades of trusted medical data and expertise, MIMS aims to enhance clinical decision-making, improve patient outcomes, and expand its global footprint. With operations in 17 markets and over two million healthcare professional subscribers, MIMS is well-positioned to drive innovation in digital health and AI-enabled solutions. As the company continues to evolve, it may set new standards for how healthcare professionals access and utilize medical information, potentially influencing how other healthcare technology companies approach product development and market expansion. For more information, visit https://corporate.mims.com/.
